Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
News|Articles|September 2, 2011
New lab glass filter dryer isolator technology
Powder Systems Ltd's (PSL's) new GFD™ isolator combines the latest innovation to provide a high containment lab scale filtration and drying solution with the same reliability and benefits as PSL high containment production size filter dryers.
Powder Systems Ltd's (PSL's) new GFD isolator combines the latest innovation to provide a high containment lab scale filtration and drying solution with the same reliability and benefits as PSL high containment production size filter dryers.
The GFD works on a vacuum, has a heated jacket for drying and a removable filtration basket for collection of the product. The new high containment system ensures operator protection and safety for the handling of highly potent and valuable products.
The GFD is available in 3 standard sizes to fulfil the needs of any lab, kilo lab or pilot plant requirement including: MINI LAB GFD (0.002m²), LAB GFD (0.01m²) and MAXI LAB GFD (0.05m²). PSL MINI and LAB GFDs are available with high containment isolation systems.
PSL is an international manufacturer of filtration, drying and high containment isolator solutions for pharmaceutical, biopharmaceutical, chemical and laboratory industries.
PSL was established 22 years ago as an original pioneer of high containment systems and can achieve containment to nanograms level. We have business units and distributors across the world to easily assist our global customer base.
Visit PSL at P-MEC Europe stand 40H59 to see the GFD Isolator.
Related to this article
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.